We are live on ! Find out more
BLTE

Belite Bio
BLTE

8 hedge funds and large institutions have $3.87M invested in Belite Bio in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more capital invested

Capital invested by funds: $2.15M → $3.87M (+$1.72M)

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

33% more funds holding

Funds holding: 6 → 8 (+2)

0.18% more ownership

Funds ownership: 0.29% → 0.46% (+0.18%)

Holders
8
Holders Change
+2
Holders Change %
+33.33%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
2
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$633K
2
State Street
State Street
Massachusetts
+$367K
3
JP Morgan Chase
JP Morgan Chase
New York
+$256K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$251K
5
Barclays
Barclays
United Kingdom
+$230K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$280K
2
BAMF
BI Asset Management Fondsmaeglerselskab
Denmark
-$92K
3
UBS Group
UBS Group
Switzerland
-$21K

BLTE Hedge Fund Activity: Q3 2022 in Review

8 of the 5,829 institutional investors tracked by Wall St. Rank reported a position in Belite Bio (BLTE) for Q3 2022, worth a combined $3.87M — up 80% from $2.15M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new BLTE positions and 3 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Morgan Stanley, opening a new position worth an estimated $633K. The largest seller was Millennium Management, exiting entirely with an estimated $280K sold.

  • 8 institutional investors held Belite Bio (BLTE) as of Q3 2022, up from 6 in Q2 2022.
  • Funds reported $3.87M of Belite Bio stock for Q3 2022, up 80% quarter-over-quarter.
  • 5 funds opened new Belite Bio positions in Q3 2022 and 3 closed out, a net change of +2 holders.
  • The largest Belite Bio buyer in Q3 2022 was Morgan Stanley, an estimated $633K added.
  • The largest Belite Bio seller in Q3 2022 was Millennium Management, an estimated $280K sold.

Based on aggregated 13F filings for Q3 2022.